Journal
NATURE
Volume 545, Issue 7655, Pages 423-431Publisher
NATURE PORTFOLIO
DOI: 10.1038/nature22395
Keywords
-
Categories
Funding
- National Cancer Institute [R01 CA114536, R01 CA136551, P01 CA59350, P30 CA008748]
Ask authors/readers for more resources
Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of synthetic receptors that reprogram lymphocyte specificity and function. CARs targeting CD19 have demonstrated remarkable potency in B cell malignancies. Engineered T cells are applicable in principle to many cancers, pending further progress to identify suitable target antigens, overcome immunosuppressive tumour microenvironments, reduce toxicities, and prevent antigen escape. Advances in the selection of optimal T cells, genetic engineering, and cell manufacturing are poised to broaden T-cell-based therapies and foster new applications in infectious diseases and autoimmunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available